Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
April 27, 2022 at 10:14 am
Share
Sunflower Pharmaceutical Group Co.,Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 1,198.47 million compared to CNY 1,216.72 million a year ago. Revenue was CNY 1,198.47 million compared to CNY 1,216.72 million a year ago. Net income was CNY 219.17 million compared to CNY 225.87 million a year ago. Basic earnings per share from continuing operations was CNY 0.38 compared to CNY 0.39 a year ago. Diluted earnings per share from continuing operations was CNY 0.38 compared to CNY 0.39 a year ago.
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Companyâs main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in domestic market.